{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:12Z","timestamp":1792791432331,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.intimp.2025.114606","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T12:13:28Z","timestamp":1743941608000},"page":"114606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MicroRNAs in patients with pemphigus: A systematic review"],"prefix":"10.1016","volume":"154","author":[{"given":"Zahra","family":"Razavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiseh","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Katebian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Aryanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Mosayebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delnia Namdari","family":"Hemmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Kianfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safoura","family":"Shakoei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10201","key":"10.1016\/j.intimp.2025.114606_bb0005","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.114606_bb0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","author":"Porro","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.intimp.2025.114606_bb0015","doi-asserted-by":"crossref","first-page":"1326359","DOI":"10.3389\/fmed.2023.1326359","article-title":"Pemphigus: trigger and predisposing factors","volume":"10","author":"Moro","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2025.114606_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2025.114606_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1672-0229(08)60044-3","article-title":"A brief review on the mechanisms of miRNA regulation","volume":"7","author":"Cai","year":"2009","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"12","key":"10.1016\/j.intimp.2025.114606_bb0030","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.autrev.2016.09.003","article-title":"The role of microRNAs in the pathogenesis of autoimmune diseases","volume":"15","author":"Chen","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2025.114606_bb0035","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-016-2167-4","article-title":"Contribution of MicroRNAs to autoimmune diseases","volume":"73","author":"Garo","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.114606_bb0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"key":"10.1016\/j.intimp.2025.114606_bb0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1684\/ejd.2017.3024","article-title":"MicroRNA in skin diseases","volume":"27","author":"Ruksha","year":"2017","journal-title":"Eur. J. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114606_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102852","article-title":"MicroRNAs in pemphigus and pemphigoid diseases","volume":"20","author":"Papara","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2025.114606_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.intimp.2025.114606_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"issue":"14","key":"10.1016\/j.intimp.2025.114606_bb0065","doi-asserted-by":"crossref","first-page":"11493","DOI":"10.3390\/ijms241411493","article-title":"Plasma Exosomal microRNA profile reveals miRNA 148a-3p downregulation in the mucosal-dominant variant of pemphigus vulgaris","volume":"24","author":"Valentino","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114606_bb0070","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.5388","article-title":"Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity","volume":"6","author":"Lin","year":"2018","journal-title":"PeerJ"},{"issue":"12","key":"10.1016\/j.intimp.2025.114606_bb0075","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.3390\/diagnostics12123058","article-title":"Identification of six microRNAs as potential biomarkers for pemphigus vulgaris: from diagnosis to pathogenesis","volume":"12","author":"He","year":"2022","journal-title":"Diagnostics"},{"issue":"7","key":"10.1016\/j.intimp.2025.114606_bb0080","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/exd.14821","article-title":"miRNA implication in the pathogenesis and the outcome of Tunisian endemic pemphigus foliaceous","volume":"32","author":"Khabou","year":"2023","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114606_bb0085","first-page":"550","article-title":"Increased expression of microRNA-338-3p contributes to production of Dsg3 antibody in pemphigus vulgaris patients","volume":"18","author":"Liu","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2025.114606_bb0090","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.3892\/mmr.2017.6422","article-title":"Increased miR-424-5p expression in peripheral blood mononuclear cells from patients with pemphigus","volume":"15","author":"Wang","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"7","key":"10.1016\/j.intimp.2025.114606_bb0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/exd.14111","article-title":"Increased expression of miR-338-3p impairs Treg-mediated immunosuppression in pemphigus vulgaris by targeting RUNX1","volume":"29","author":"Xu","year":"2020","journal-title":"Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114606_bb0100","first-page":"6461","article-title":"MiR-127 regulates the development of oral pemphigus by targeting IL-6","volume":"10","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.114606_bb0105","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2025.114606_bb0110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fmed.2018.00296","article-title":"Diagnosis of autoimmune blistering diseases","volume":"5","author":"Witte","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2025.114606_bb0115","doi-asserted-by":"crossref","unstructured":"Belloni-Fortina, A., et al., Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. J. Immunol. Res., 2009. 2009.","DOI":"10.1155\/2009\/187864"},{"issue":"10","key":"10.1016\/j.intimp.2025.114606_bb0120","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/ijd.12662","article-title":"Do normal Egyptians possess anti-desmoglein 3 antibodies?","volume":"54","author":"Saleh","year":"2015","journal-title":"Int. J. Dermatol."},{"issue":"46","key":"10.1016\/j.intimp.2025.114606_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008801","article-title":"Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission","volume":"96","author":"Russo","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.intimp.2025.114606_bb0130","series-title":"Desmoglein ELISA in the Diagnosis of Pemphigus and its Correlation with the Severity of Pemphigus Vulgaris","author":"Mortazavi","year":"2009"},{"issue":"7","key":"10.1016\/j.intimp.2025.114606_bb0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrrheum.2010.81","article-title":"MicroRNAs as biomarkers in rheumatic diseases","volume":"6","author":"Alevizos","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114606_bb0140","first-page":"477","article-title":"T and B lymphocytes in south American pemphigus foliaceus","volume":"23","author":"Guerra","year":"1976","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2025.114606_bb0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00403-006-0661-5","article-title":"Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases","volume":"298","author":"Echigo","year":"2006","journal-title":"Arch. Dermatol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114606_bb0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1523-1747.2000.00840.x","article-title":"Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production","volume":"114","author":"Nishifuji","year":"2000","journal-title":"J. Invest. Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114606_bb0155","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.3390\/ijms24119130","article-title":"The essential role of micrornas in inflammatory and autoimmune skin diseases\u2014a review","volume":"24","author":"Dopytalska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2025.114606_bb0160","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1007\/s11033-019-05053-6","article-title":"Expression of human endogenous retroviruses in pemphigus vulgaris patients","volume":"46","author":"Karimi","year":"2019","journal-title":"Mol. Biol. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2025.114606_bb0165","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2174\/1566524023666230418114152","article-title":"Association of Human Endogenous Retrovirus-W (HERV-W) copies with pemphigus vulgaris","volume":"24","author":"Semsari","year":"2024","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.intimp.2025.114606_bb0170","doi-asserted-by":"crossref","first-page":"9505312","DOI":"10.1155\/2020\/9505312","article-title":"miR-1291 functions as a potential serum biomarker for bullous pemphigoid","volume":"2020","author":"Qiu","year":"2020","journal-title":"Dis. Markers"},{"issue":"6","key":"10.1016\/j.intimp.2025.114606_bb0175","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14380","article-title":"Investigating expression pattern of eight immune-related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy","volume":"33","author":"Tavakolpour","year":"2020","journal-title":"Dermatol. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692500596X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692500596X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T23:24:51Z","timestamp":1744500291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692500596X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":35,"alternative-id":["S156757692500596X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114606","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNAs in patients with pemphigus: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114606"}}